These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 29192)

  • 1. Effects of dopaminergic agonists and antagonists on cerebellar guanosine-3',5'-monophosphate (cGMP).
    Breese GR; Mailman RB; Ondrusek MG; Harden TK; Mueller RA
    Life Sci; 1978 Aug; 23(5):533-6. PubMed ID: 29192
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of dopaminergic agonists and antagonists on in vivo cyclic nucleotide content: relation of guanosine 3':5'- monophosphate (cGMP) changes in cerebellum to behavior.
    Breese GR; Mueller RA; Mailman RB
    J Pharmacol Exp Ther; 1979 May; 209(2):262-70. PubMed ID: 35602
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of chronic treatment with neuroleptics on the content of 3',5'-cyclic guanosine monophosphate in cerebellar cortex of rats.
    Biggio G; Corda MG; Casu M; Gessa GL
    Life Sci; 1978 Aug; 23(6):649-52. PubMed ID: 29201
    [No Abstract]   [Full Text] [Related]  

  • 4. CCK modulation of cerebellar afferents: dopaminergic involvement.
    Wood PL
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(3-4):513-8. PubMed ID: 2546180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the mechanism of the decrease in cerebellar cyclic GMP content elicited by opiate receptor agonists.
    Biggio G; Guidotti A; Costa E
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Jan; 296(2):117-21. PubMed ID: 189228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of rat cerebellar guanosine 3',5'-cyclic phosphate by dopaminergic mechanisms in vivo.
    Burkard WP; Pieri L; Haefely W
    Adv Biochem Psychopharmacol; 1976; 15():315-24. PubMed ID: 192051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kainic acid-induced lesion of dopaminergic target cells in the striatum: consequences on the dynamics of cerebellar cGMP.
    Biggio G; Corda MG; Casu M; Gessa GL
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Aug; 304(1):5-7. PubMed ID: 211448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologically induced changes in the 3':5'-cyclic guanosine monophosphate content of rat cerebellar cortex: difference between apomorphine, haloperidol and harmaline.
    Biggio G; Costa E; Guidotti A
    J Pharmacol Exp Ther; 1977 Jan; 200(1):207-15. PubMed ID: 13199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical interactions of competitive N-methyl-D-aspartate antagonists with dopaminergic neurotransmission and the cerebellar cyclic GMP system: functional evidence for a phasic glutamatergic control of the nigrostriatal dopaminergic pathway.
    Rao TS; Cler JA; Mick SJ; Emmett MR; Farah JM; Contreras PC; Iyengar S; Wood PL
    J Neurochem; 1991 Mar; 56(3):907-13. PubMed ID: 1847188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striato-cerebellar pathway controlling cyclic GMP content in the cerebellum: role of dopamine, GABA and enkephalins.
    Biggio G; Corda MG; Casu M; Gessa GL
    Adv Biochem Psychopharmacol; 1978; 18():227-44. PubMed ID: 206110
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of drugs which alter GABA-ergic function on cerebellar guanosine-3',5'-monophosphate content.
    Mailman RB; Mueller RA; Breese GR
    Life Sci; 1978 Aug; 23(6):623-7. PubMed ID: 211362
    [No Abstract]   [Full Text] [Related]  

  • 12. Lithium antagonism of ethanol-induced depletion of cerebellar guanosine-3',5'-cyclic monophosphate and stimulation of striatal dopamine release.
    Hunt WA; Goldman ME
    J Stud Alcohol; 1979 May; 40(5):401-7. PubMed ID: 224268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo effects of noradrenaline and noradrenergic receptor agonists and antagonists on rat cerebellar cyclic GMP levels.
    Haidamous M; Kouyoumdjian JC; Briley PA; Gonnard P
    Eur J Pharmacol; 1980 May; 63(4):287-94. PubMed ID: 6104602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of general central nervous system depressants with and without calcium ionophore A23187 of rat cerebellar cyclic guanosine 3',5'-monophosphate.
    Dodson RA; Johnson WE
    Res Commun Chem Pathol Pharmacol; 1980 Aug; 29(2):265-80. PubMed ID: 6251522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethanol-induced depletion of cerebellar guanosine 3',5' -cyclic monophosphate.
    Redos JD; Catravas GN; Hunt WA
    Science; 1976 Jul; 193(4247):58-9. PubMed ID: 180596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo changes of guanosine 3',5'-cyclic phosphate in rat cerebellum by dopaminergic mechanisms.
    Burkard WP; Pieri L; Haefely W
    J Neurochem; 1976 Jul; 27(1):297-8. PubMed ID: 182922
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopaminergic stimulants and cyclic nucleotides in mouse brain. Effects of dopaminergic antagonists, cholinolytics, and GABA agonists.
    Gumulka SW; Dinnendahl V; Schönhöfer PS; Stock K
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Oct; 295(1):21-6. PubMed ID: 187962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in brain guanosine 3',5'-monophosphate (cGMP) content by thyrotropin-releasing hormone.
    Mailman RB; Frye GD; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1979 Feb; 208(2):169-75. PubMed ID: 33261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of desmethyldiazepam and chlordesmethyldiazepam on 3',5'-cyclic guanosine monophosphate levels in rat cerebellum.
    Govoni S; Fresia P; Spano PF; Trabucchi M
    Psychopharmacology (Berl); 1976 Nov; 50(3):241-4. PubMed ID: 188062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of guanosine 3',5'-monophosphate level by adenosine in cerebellar slices of guinea pig.
    Saito M
    Biochim Biophys Acta; 1977 Jul; 498(1):316-24. PubMed ID: 195632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.